Sandbox Reserved 425: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Lynmarie K Thompson, Student

Revision as of 22:22, 9 April 2016 view source Student (talk \| contribs) students 33,700 edits No edit summary ← Older edit		Revision as of 22:22, 9 April 2016 view source Student (talk \| contribs) students 33,700 edits No edit summary Newer edit →
Line 45:		Line 45:
	The brand name for ponatinib is Iclusig. Iclusig received an accelerated approval grant through the Food and Drug Administration. It was mainly prescribed to patients suffering from CML or ALL who did not make any progress with the first and second generation TKIs. However, the clinical trials data revealed a spike in adverse effects. These consequences include heart failure, stroke, coronary artery disease, loss of blood flow to body parts leading to amputation amongst other narrowing of blood vessels<ref>FDA Drug Safety Communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins; Drug Safety and Availability; United States Food and Drug Administration (2013). Web. [http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm]</ref>.		The brand name for ponatinib is Iclusig. Iclusig received an accelerated approval grant through the Food and Drug Administration. It was mainly prescribed to patients suffering from CML or ALL who did not make any progress with the first and second generation TKIs. However, the clinical trials data revealed a spike in adverse effects. These consequences include heart failure, stroke, coronary artery disease, loss of blood flow to body parts leading to amputation amongst other narrowing of blood vessels<ref>FDA Drug Safety Communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins; Drug Safety and Availability; United States Food and Drug Administration (2013). Web. [http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm]</ref>.

	FGFR-4 is abundantly present in human prostate cancer observed in vitro and mouse models. A variant of FGFR-4 with (Arg(388)) replacing (Gly(388)) is associated with increased human prostate cancer. This causes increased receptor stability and activation<ref name="three">~~PMID~~:PMC4654778</ref>		FGFR-4 is abundantly present in human prostate cancer observed in vitro and mouse models. A variant of FGFR-4 with (Arg(388)) replacing (Gly(388)) is associated with increased human prostate cancer. This causes increased receptor stability and activation<ref name="three">PMCID:PMC4654778</ref>